Angiotensin II Increases Plasminogen Activator Inhibitor-1 and Tissue Factor mRNA Expression without Changing that of Tissue Type Plasminogen Activator or Tissue Factor Pathway Inhibitor in Cultured Rat Aortic Endothelial Cells

Summary

Angiotensin converting enzyme inhibitors (ACE-I) have been reported to prevent the recurrence of cardiovascular events. The mechanism of this decrease, however, can not be completely explained by anti-hypertensive and anti-hypertrophic effects of ACE-I. To investigate the mechanism of this decrease, we studied the regulation of plasminogen activator inhibitor-1 (PAI-1), tissue type plasminogen activator (TPA), tissue factor (TF), and tissue factor pathway inhibitor (TFPI) by angiotensin II (Ang II) in cultured rat aortic endothelial cells. Ang II increased PAI-1 and TF mRNA expression without affecting that of TPA or TFPI. These inductions were accompanied by increases in PAI-1 and TF activities and were inhibited by a type 1 Ang II receptor antagonist. The results suggest that Ang II decreases the antithrombotic properties of endothelial cells which increases the chance of thrombosis. Thus, inhibition of the renin-angiotensin system may be beneficial to prevent thrombus formation in treatment of ischemic heart disease.

• References

• 1 Johnston CI. Biochemistry and pharmacology of renin-angiotensin system. Drugs 1990; 39 (Suppl. 01) 21-31
• 2 Peach MJ, Dostal DE. The angiotensin II receptor and the actions of angiotensin II. J Card Pharmacol 1990; 16: 525-530
• 3 Graves H, Brown JJ, Lever AF, Macadam RF, Rovertson JIS. Acute renal failure, tubular necrosis and myocardial infarction induced into the rabbit by intravenous angiotensin-II. Lancet 1971; ii: 19-22
• 4 Pfeffer MA, Braunwald E, Moye LA. et al, for the SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677
• 5 Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with ejections. Lancet 1992; 340: 1173-1178
• 6 Loskutoff DJ, Van MourikJA, Erickson LA, Lawrence A. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
• 7 Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor-1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
• 8 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 9 Luskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 09: 87-115
• 10 Pannekoek H, Veeman H, Lambosis H, Diergaarde P, Verwiji CL, van ZonneveldAJ, Van MourikJA. Endothlial plasminogen activator inhibitor (PAI-1):a new member of serpin gene family. EMBO (Eur Mol Biol Org) J 1986; 05: 2539-2544
• 11 Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. 03. ^rded. J B Lippincott Company; Philadelphia, PA: 1994. pp 1076-1103
• 12 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in transgenic mice for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76
• 13 Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diatheses due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1745-1752
• 14 Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report:complete deficiency of plasminogen activator inhibitor type 1 due to a frame shift mutation. N Engl J Med 1992; 327: 1729-1733
• 15 Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A life long bleeding disorder associated with a deficiency of plasminogen activator inhibitor type I. Blood 1991; 77: 528-532
• 16 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De VosR, van denOordJJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424
• 17 Marder VJ, Sherry S. Thrombolytic therapy:Current status. N Engl J Med 1988; 318: 1512-1520
• 18 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
• 19 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
• 20 Rapaport SI. The extrinsic pathway inhibitor:A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15
• 21 Bach RR. Initiation of coagulation by tissue factor. Crit Rev Biochem 1988; 23: 339-368
• 22 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79
• 23 William FN. Tissue factor pathway inhibitor. Semin Thromb Hemost 1994; 20: 101-108
• 24 Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitors of factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878
• 25 Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Deletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor:Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-712
• 26 Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin induced intravascular coagulation and the generalized Schwartzman reaction. Blood 1991; 78: 1496-1502
• 27 Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
• 28 Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266
• 29 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo:Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 1991; 88: 1346-1353
• 30 Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I:Implication for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88: 9959-9963
• 31 Medcalf RL, van denBerg E, Schleuning WD. Glucocorticoid modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol 1988; 106: 971-978
• 32 Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. J Biol Chem 1989; 264: 20705-20713
• 33 Grossman DC, Car DP, Toddenham GD, Pearson JD, McVey JH. The regulation of TF mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem 1990; 265: 9782-9787
• 34 Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53: 231-241
• 35 Nawroth PP, DM Stern. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
• 36 Nawroth PP, Handley DA, Esmon CT, Stem DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-3464
• 37 Ameri A, Kuppuswamy MK, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992; 79: 3219-3226
• 38 Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-839
• 39 McGuire PG, Orkin RW. Methods in laboratory investigation Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab Invest 1987; 57: 94-105
• 40 Thomas PS. Hybridization of denatured RNA and small DNA fragments to nitrocellulose. Proc Natl Acad Sci USA 1983; 77: 5201-5205
• 41 Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73: 459-468
• 42 Ny T, Leonardsson G, Hsueh AJW. Cloning and characterization of cDNA for rat tissue-type plasminogen activator. DNA 1988; 07: 671-677
• 43 Rosenfield CL. Rattus norvegicus Sprague-Dawley tissue factor protein mRNA, complete eds. GenBank accession. 1994: U07619
• 44 Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem 1992; 111: 681-687
• 45 Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs:Genomic complexity and molecular evolution of the gene. Nucleic Acid Res 1985; 13: 2485-2502
• 46 Olson JA, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metal-loprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci USA 1991; 88: 1928-1932
• 47 Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-2520
• 48 Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001
• 49 van LeeuwenRTJ, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-368
• 50 Taubman MB, Marmur JD, Rosenfield C, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. J Clin Invest 1993; 91: 547-552
• 51 Hermann K, Ganten D, Unger T, Bayer C, Lang RE. Measurement and characterization of angiotensin peptides in plasma. Clin Chem 1988; 34: 1046-1051
• 52 Simon D, Romestand B, Huang H, Badouaille G, Fehrentz HA, Pau B, Marchand J, Corval P. Direct simplified and sensitive assay of angiotensin II in plasma extracts performed with a high-affinity monoclonal antibody. Clin Chem 1992; 38: 1963-1967
• 53 Schunkert H, Ingelfinger JR, Hirsh AT, Tang SS, Litwin SE, Talsness CE, Dazu VJ. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90: 1523-1529
• 54 Griendling KK, Lassègue B, Alexander RW. The vascular angiotensin (ATI) receptor. Thromb Haemost 1993; 70 (01) 188-192
• 55 Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-236
• 56 Wong PC, Price WA, Chiu AT, Duncia AV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonists VIII1 characterization of functional antagonism displayed by Dup 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1989; 252 (02) 719-725
• 57 Drake TA, Morrissey JH, Edington TS. Selective cellular expression of tissue factor in human tissues. Implication for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097
• 58 Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherosclerosis. Thromb Haemost 1993; 70: 138-143
• 59 Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem 1994; 269: 14149-14152